SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Arrowhead Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Arrowhead Pharmaceuticals, Inc. (“Arrowhead” or the “Company”) (Nasdaq: ARWR) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Arrowhead shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation focuses on whether Arrowhead and certain of its officers and/or directors violated federal securities laws. On November 8, 2016, the Company revealed that the U.S. Food & Drug Administration will be placing a clinical hold on its Heparc-2004 clinical study of ARC-520, likely due to deaths at the highest dose of an ongoing non-human primate toxicology study. When this news was announced, shares of Arrowhead fell in value.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161109006440/en/